[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-nervous-system-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-nervous-system-cancer":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,100,128,159,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":77,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100210159","integrated-cancer-repository-for-cancer-research-100210159",false,"NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"ALL","19 Years","110 Years",{"count":21,"type":22},999999,"ESTIMATED","80 Years","OBSERVATIONAL","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76],"Pancreatic Cancer","Thyroid Cancer","Lung Cancer","Esophageal Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Anal Cancer","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Liver Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Kidney Cancer","Penile Cancer","Prostate Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Leukemia","Melanoma","Sarcoma","Unknown Primary Tumor","Multiple Myeloma","Ovarian Cancer","Endometrial Cancer","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[27,28,78,79,80,81,82,83,84,85,65,86,75,76],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","RECRUITING","2026-06-25",{"date":90,"type":91},"2026-06-29","ACTUAL",{"date":93,"type":91},"2013-11-01",{"date":95,"type":22},"2099-12",{"name":97,"class":98},"University of Nebraska","OTHER",42,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100604258","short-course-radiotherapy-100604258","NCT07147179","Short Course Radiotherapy","Pilot Trial of Short Course Radiotherapy for Primary or Secondary CNS Malignancies","Inclusion Criteria:\n\n* Male or female, aged 21 years or below\n* Lansky performance status \\>= 40\n* Has a diagnosis of an incurable malignancy that:\n\n  * Originates outside the brain but is metastatic to 1 or more sites within the brain, or originates and recurs within the brain. For this diagnosis to be confirmed, there must be multidisciplinary review of up to date imaging at a pediatric tumor board with unanimous consensus of intracranial relapse or metastasis. If the consensus is not unanimous, short-interval repeat imaging with subsequent unanimous consensus would be required in order for this eligibility criteria to be met\n  * Has at least 1 targetable intracranial lesion as seen on imaging\n  * Has a multidisciplinary consensus recommendation for palliative intent radiation\n* Consents to the study or has caregiver who is able to provide signed and dated informed consent. For subjects under the age of 18, a signed and dated assent form as able.\n* Patients who had prior radiation in planned treatment area are also eligible to enter the trial\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n* Radiotherapy for curative intent\n* Serious uncontrolled systemic or psychiatric disorders that would interfere with participation in the protocol\n* Being planned for proton radiation","21 Years",{"count":109,"type":22},15,"INTERVENTIONAL",[112],"NA","This is a single arm prospective pilot trial determining the safety of short-course radiation therapy in pediatric patients with incurable central nervous system malignancies.",[63],[116,117],"Short Course","Radiotherapy","2026-04-29",{"date":120,"type":91},"2026-05-05",{"date":122,"type":91},"2026-04-02",{"date":124,"type":22},"2027-03",{"name":126,"class":98},"Abramson Cancer Center at Penn Medicine",1,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":110,"phases":138,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":127},"100628505","phase-2-inflammation-in-primary-and-secondary-malignancies-of-the-central-nervous-system-using-c-11-cs1p1-100628505","NCT07462507","Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1","Investigation of Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1","Inclusion Criteria:\n\n* Male or female, any race\n* Age ≥ 18 years\n* Capable of providing written informed consent OR having a legally authorized representative (LAR) to provide informed consent for volunteering to undergo research procedure\n* Has a clinical, radiographic, or pathological diagnosis of primary or secondary CNS malignancy that has not been treated with radiotherapy\n\nExclusion Criteria:\n\n* Hypersensitivity to \\[C-11\\]-CS1P1 or any of its excipients\n* Contraindications to PET, CT or MRI (e.g. certain incompatible electronic medical devices, inability to lie still for extended periods) that make it potentially unsafe for the individual to participate\n* Prior cranial radiotherapy\n* Severe claustrophobia that would require general anesthesia\n* Women who are currently pregnant or breastfeeding\n* Any condition that, in the opinion of the Sponsor-Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with the collection of the data (e.g., advanced renal or liver failure)\n* Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1. https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcdrh\u002Fcfdocs\u002Fcfcfr\u002FCFRSearch.cfm?FR=361.1.","18 Years",{"count":137,"type":22},104,[139],"PHASE2","Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline \\[C-11\\]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatment).The study will describe patterns of tracer uptake in tumors and normal brain and explore how these patterns relate to MRI findings, treatments received, and clinical outcomes.",[63,142],"Brain Metastases",[144,145,146,147,148,149],"Primary brain tumor","Glioma","Glioblastoma","Astrocytoma","Oligodendroglioma","Brain metastasis","2026-04-17",{"date":152,"type":91},"2026-04-21",{"date":154,"type":91},"2026-04-16",{"date":156,"type":22},"2033-06-30",{"name":158,"class":98},"Washington University School of Medicine",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":110,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":127},"100553378","interest-of-a-teteleconsultation-of-a-psychological-support-nurse-on-psychological-distress-in-patients-with-a-primary-malignancy-of-the-central-nervous-system-100553378","NCT06485310","Interest of a TEteleconsultation of a Psychological Support Nurse on Psychological Distress in Patients With a Primary Malignancy of the Central Nervous System","Interest of a TEteleconsultation of a Psychological Support Nurse on Psychological Distress in Patients With a Primary Malignancy of the Central Nervous System Between the Announcement of the Diagnosis and the First Treatment","TECAP","Inclusion Criteria:\n\n* aged 18 and over\n* being treated for a primary malignant tumor of the central nervous system (positive biopsy)\n* with a Mini-Mental State score greater than 24\n* not receiving first-line treatment (chemotherapy, targeted radiotherapy, surgery)\n* with a distress score above 3 on the Psychological Distress Thermometer\n* have access to computer equipment equipped with a microphone and webcam (smartphone, computer)\n* able to read, write and speak French\n* have given free and informed consent\n* being affiliated to a social security scheme\n\nExclusion Criteria:\n\n* with a history of psychiatric illness\n* with recurrent cancer of the cerebral nervous system\n* having begun first-line treatment (drug therapy, curative surgery, radiotherapy or palliative care)\n* under guardianship, curatorship or deprived of liberty",{"count":168,"type":22},58,[112],"The goal of this clinal trial is to compare the effectiveness of nurse-led teleconsultation with usual care (intervention group) on psychological distress in patients with primary malignant tumors of the central nervous system between diagnosis and first anti-cancer treatment, versus usual care alone (control group).\n\nParticipants will be randomized into two groups :\n\n* group A) intervention: usual care + nurse teleconsultation for psychological support\n* group B) control: usual care alone\n\nEnrolment = Day0 (D0)\n\nParticipants will :\n\n* groups A and B: D0: complete 4 questionnaires (Quality of Life, Screening for Distress, Screening for Anxiety and Depression, Social Support Questionnaire)\n* Group A : D0+2\u002F4 das : nursing teleconsultation for psychological support\n* Groups A and B: D0+10days : telephone call to complete the same 4 questionnaires as at inclusion\n* Group A : D0+15days: semi-directive interview, at home, for voluntary patients.",[63,172],"Psychological Distress","NOT_YET_RECRUITING","2026-01-16",{"date":176,"type":91},"2026-01-20",{"date":178,"type":22},"2026-03-31",{"date":180,"type":22},"2028-06-30",{"name":182,"class":98},"Centre Hospitalier Universitaire de la Réunion",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":127},"100456097","cns-qualitative-interview-100456097","NCT05219149","CNS Qualitative Interview","Exploring Factors in Patient and Family Consideration of Treatment for Pediatric Central Nervous System Tumors","Inclusion Criteria:\n\n1. Be the parent or caregiver of a child or young adult receiving treatment at CHCO\n\n   a. Child must meet one criterion below: i. Newly diagnosed with a CNS tumor ii. Relapse of a CNS tumor requiring further therapy. Therapy may be standard of care of dictated by an open clinical trial\n2. Patient 18 years of age or older a. Must meet one of the criteria below: i. Newly diagnosed with a CNS tumor ii. Relapse of a CNS tumor requiring further therapy. Therapy may be standard of care of dictated by an open clinical trial\n\nExclusion Criteria:\n\n* Does not meet inclusion criteria",{"count":191,"type":22},20,"Explore factors involved in decision making for patients with new or recurrent CNS tumors and their families surrounding treatment planning and clinical trial enrollment.",[63],"2025-08-13",{"date":196,"type":91},"2025-08-17",{"date":198,"type":91},"2022-01-03",{"date":200,"type":22},"2026-07-23",{"name":202,"class":98},"University of Colorado, Denver"]